Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Ebola Virus - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The comprehensive report on the "Ebola Virus Competitive Landscape 2026" offers a deep dive into the market, chronicling the current scenario and the trajectory for therapeutics targeting Ebola virus disease. This analysis spans across over 18 companies and 20 drugs, delving into product types, development stages, routes of administration, and molecule types, while also addressing inactive pipeline products.
Geographical Coverage: Global
Ebola virus manifestations include initial flu-like symptoms that can escalate to severe conditions such as vomiting, hemorrhaging, and neurological complications. The zoonotic virus often leads to human outbreaks mainly in Africa, with bats as the likely natural reservoir. Upon human infection, the virus disrupts the immune system, causing severe inflammatory responses, organ dysfunction, and, in many cases, death. The diagnosis involves clinical assessments and laboratory confirmations such as PCR tests.
Treatment focuses on maintaining vital functions, with antiviral treatments like remdesivir and monoclonal antibodies such as Inmazeb showing promise. Vaccines like rVSV-ZEBOV are employed in outbreak zones to curb virus spread. Despite advancements, early intervention and care are pivotal to boosting survival rates.
Report Highlights
- In May 2024, RedHill was granted a Chinese patent for opaganib by the CNIPA, covering single-stranded RNA virus replication inhibition till 2035.
- In November 2023, SK bioscience partnered with Hilleman Laboratories Singapore to develop a cost-effective second-generation Ebola-Zaire vaccine.
- In October 2023, RedHill Biopharma reported that oral opaganib significantly improved survival times in an in vivo Ebola virus study by the USAMRIID.
Ebola Virus: Company and Product Profiles (Marketed Therapies)
Regeneron Pharmaceuticals, headquartered in Tarrytown, NY, is recognized for its innovative treatments across several serious conditions. Among their key products is Inmazeb, a monoclonal antibody cocktail developed using their VelocImmune technology to neutralize the Ebola virus.
Ebola Virus: Company and Product Profiles (Pipeline Therapies) 1. INOVIO Pharmaceuticals
INO 4201 is a DNA vaccine targeting the Zaire Ebola virus glycoprotein, evaluated in a Phase 1b trial for safety and immunogenicity in participants previously vaccinated with Ervebo.
Auro Vaccines
A company pioneering in vaccine development using the VesiculoVaxT platform. Their Ebola virus vaccine has completed a Phase I trial, demonstrating safety and full immunogenicity.
RedHill Biopharma Ltd.
RedHill is focused on infectious diseases and has shown promising results with its investigational drug, Opaganib, which increases survival time in Ebola virus studies.
Ebola Virus Analytical Perspective
This report provides a detailed commercial assessment, including collaborations, agreements, and acquisition analysis. It compares companies by therapy, development stage, and technology, and covers unmet needs and key questions about the current treatment scenario and emerging therapies.
Key Players
- Auro Vaccines
- INOVIO Pharmaceuticals
- RedHill Biopharma Ltd.
- Emergent BioSolutions
- Arisan Therapeutics
- TFF Pharmaceuticals
- China Immunotech
Key Products
- Ebola virus vaccine
- INO 4201
- Opaganib
- RHB-107
- Pan - Ebola
- ARN 75092
- Research Programme: Viral vaccines
- EBV TCR T cell therapy
Key Topics Covered:
Introduction
Executive Summary
Ebola Virus: Overview
- Introduction
- Classification
- Risk factors
- Diagnosis
- Treatment
Ebola Virus-Analytical Perspective: In-depth Commercial Assessment
- Ebola Virus Collaboration Analysis by Companies
Competitive Landscape
- Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Ebola Virus: Company and Product Profiles (Marketed Therapies)
Regeneron Pharmaceuticals
- Company Overview
Inmazeb
- Product Description
- Research and Development Activities
- Product Developmental Activities
Ebola Virus: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
- Comparative Analysis
Company Name
- Company Overview
Drug Name
- Product Description
- Research and Development Activities
- Product Developmental Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Company Name
- Company Overview
Drug Name
- Product Description
- Research and Development Activities
- Product Developmental Activities
Early Stage Products (Phase I)
- Comparative Analysis
INOVIO Pharmaceuticals
- Company Overview
INO 4201
- Product Description
- Research and Development Activities
- Product Developmental Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
RedHill Biopharma Ltd.
- Company Overview
Opaganib
- Product Description
- Research and Development Activities
- Product Developmental Activities
Inactive Products
- Comparative Analysis
Ebola Virus- Unmet needs
Ebola Virus- Market drivers and barriers
For more information about this report visit https://www.researchandmarkets.com/r/j2jum2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
